Companies · AI / ML
Santa Monica · AI / ML · refined from filed group “Other Technology” · founded 2022 · https://glass.health
Diligence memoA one-page analyst read on Glass Health, Inc. — recommendation, valuation, rhythm, risks.→Glass Health, Inc. looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the ai/ml sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Glass Health, Inc. is one of 2067 AI / ML companies tracked from Santa Monica, on record since 2022. By capital raised it ranks in the upper tier (ahead of 87% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
AI-Powered Clinical Decision Support & Ambient Scribing
We empower clinicians with our AI platform for developing differential diagnoses and drafting clinical plans.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the ai/ml sector profile. Directional, not a quoted figure.
Benchmarked against 2067 companies in AI / ML. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 87% of sector peers (real $). Modeled value above 93% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #20 of 48.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| TARA Intelligence Inc. | Series A | $12.6M | $455.2M | 2.26× |
| Castle Intelligence, Inc. | Series A | $11.7M | $423.4M | 2.10× |
| CrowdAI, Inc. | Series A | $10.1M | $365.0M | 1.81× |
| Socrates AI, Inc. | Series A | $21.0M | $361.3M | 1.79× |
| Roger.ai, Inc. | Series A | $9.6M | $346.3M | 1.72× |
| Cohort Intelligence Corp | Series A | $11.5M | $342.0M | 1.70× |
| Superb AI, Inc. | Series A | $11.5M | $329.0M | 1.63× |
| Intelligencia Inc. | Series A | $13.8M | $304.6M | 1.51× |
| Clearview AI, Inc. | Series A | $8.6M | $299.5M | 1.49× |
| Resistant Ai, Inc. | Series A | $12.5M | $294.3M | 1.46× |
| Sila Inc. | Series A | $10.7M | $279.7M | 1.39× |
| Root AI, Inc. | Series A | $7.9M | $276.2M | 1.37× |
| Glass Health, Inc. this company | Series A | $8.8M | $226.8M | 1.13× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $2.6M | 2015-11-03 | $12.8M | $113.3M | 90% |
| Seed | $1.2M | 2015-11-03 | $6.2M | $55.1M | 85% |
| Series A | $6.3M | 2019-08-09 | $28.5M | $226.8M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Hari Sundram | — | 3 other | 2015-11 |
| Matthew Kinley | — | 3 other | 2019-08 |
| Jeffrey Parkinson | — | 2 other | 2015-11 |
| Brett Plotzker | — | — | 2015-11 |
| Brett Plozker | — | — | 2015-11 |
| Jeremy Bluvol | — | — | 2015-11 |
Glass Health, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Poolday AI, Inc. | AI / ML | Series A | $8.7M | $19.5M | same sector · same stage |
| Elea.ai, Inc | AI / ML | Series A | $9.0M | $32.4M | same sector · same stage |
| Kinta Artificial Intelligence, Inc. | AI / ML | Series A | $9.0M | $146.3M | same sector · same stage |
| MachGen AI, Inc. | AI / ML | Series A | $9.0M | $26.3M | same sector · same stage |
| Clearview AI, Inc. | AI / ML | Series A | $8.6M | $299.5M | same sector · same stage |
| GCP AI InvestCo, LLC | AI / ML | Series A | $8.5M | $86.8M | same sector · same stage |
| Scala.ai, Inc. | AI / ML | Series A | $8.5M | $25.7M | same sector · same stage |
| ConverSight.ai, Inc. | AI / ML | Series A | $9.2M | $53.7M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Vera Health AI-powered clinical decision support for healthcare providers | AI / ML | — | — | 82% |
| Thrive AI Health, Inc. | AI / ML | Series A | $48.0M | 81% |
| RIVR Health AI, Inc. | AI / ML | Seed | $3.0M | 81% |
| DOC.AI Inc | AI / ML | Seed | $101.0M | 81% |
| Healthcare AI Automation, Inc. | AI / ML | Seed | $11.3M | 80% |
| Orchid AI-powered EHR for independent mental health professionals | Healthtech | — | — | 80% |
| Akido Labs, Inc. Rebuilding healthcare with AI at the core | AI / ML | Series C | $676.4M | 79% |
| Adravision Automation for dental clinics and insurance companies. | Medical Devices | — | — | 79% |
See where Glass Health, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Glass Health, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.